Characterization of protoberberine analogs employed as novel human P2X7 receptor antagonists

Toxicol Appl Pharmacol. 2011 Apr 15;252(2):192-200. doi: 10.1016/j.taap.2011.02.009. Epub 2011 Feb 12.

Abstract

The P2X(7) receptor (P2X(7)R), a member of the ATP-gated ion channel family, is regarded as a promising target for therapy of immune-related diseases including rheumatoid arthritis and chronic pain. A group of novel protoberberine analogs (compounds 3-5), discovered by screening of chemical libraries, was here investigated with respect to their function as P2X(7)R antagonists. Compounds 3-5 non-competitively inhibited BzATP-induced ethidium ion influx into hP2X(7)-expressing HEK293 cells, with IC(50) values of 100-300nM. This antagonistic action on the channel further confirmed that both BzATP-induced inward currents and Ca(2+) influx were strongly inhibited by compounds 3-5 in patch-clamp and Ca(2+) influx assays. The antagonists also effectively suppressed downstream signaling of P2X(7) receptors including IL-1β release and phosphorylation of ERK1/2 and p38 proteins in hP2X(7)-expressing HEK293 cells or in differentiated human monocytes (THP-1 cells). Moreover, IL-2 secretion from CD3/CD28-stimulated Jurkat T cell was also dramatically inhibited by the antagonist. These results imply that novel protoberberine analogs may modulate P2X(7) receptor-mediated immune responses by allosteric inhibition of the receptor.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Berberine Alkaloids / chemistry*
  • Berberine Alkaloids / pharmacology*
  • Dose-Response Relationship, Drug
  • HEK293 Cells
  • Humans
  • Jurkat Cells
  • Purinergic P2 Receptor Antagonists / chemistry*
  • Purinergic P2 Receptor Antagonists / pharmacology*
  • Receptors, Purinergic P2X7* / metabolism
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Berberine Alkaloids
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2X7
  • protoberberine